Piper Sandler Reaffirms “Overweight” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating restated by stock analysts at Piper Sandler in a research report issued on Friday,Benzinga reports. They currently have a $58.00 price objective on the biotechnology company’s stock, up from their previous price objective of $45.00. Piper Sandler’s price objective points to a potential upside of 87.12% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. iA Financial set a $48.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and an average target price of $44.91.

Capricor Therapeutics Trading Down 7.3%

Shares of NASDAQ:CAPR traded down $2.42 on Friday, reaching $31.00. 1,598,876 shares of the company were exchanged, compared to its average volume of 1,333,494. The company has a 50-day moving average of $25.66 and a 200-day moving average of $16.35. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -17.19 and a beta of 0.37. Capricor Therapeutics has a 1-year low of $4.30 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in shares of Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 557 shares during the last quarter. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $43,000. Nuveen LLC lifted its holdings in Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 1,878 shares during the period. State of Wyoming boosted its holdings in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares in the last quarter. Finally, GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter valued at $59,000. Institutional investors own 21.68% of the company’s stock.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of deramiocel and set an August decision window, reviving the pathway for approval and reducing some regulatory uncertainty. Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the 2026 MDA conference showed significant functional benefits for deramiocel in Duchenne muscular dystrophy — a clinical readout that supports the therapy’s commercial potential if approved. HOPE-3 Data Press Release
• Positive Sentiment: HC Wainwright reiterated a Buy rating on CAPR, which can provide support from buy-side interest and signal confidence to some investors. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Neutral Sentiment: Company filed its fourth-quarter and full-year 2025 results and provided a corporate update; the release contains financial details and operational commentary investors will parse for runway and milestones. Q4 & Full-Year 2025 Results
• Neutral Sentiment: Q4 2025 earnings call transcript and supplemental materials are available for detailed management commentary and Q&A — useful for assessing guidance, cash runway and commercialization planning. Earnings Call Transcript
• Neutral Sentiment: News outlets flagged “earnings on deck” coverage following the FDA review resumption — media attention can amplify both upside and downside moves depending on follow-up items. Investing.com Coverage
• Neutral Sentiment: Recent short-interest reports show anomalous “0 shares” figures and a 0.0 days-to-cover metric — likely data noise rather than a material shift in short positioning. (Multiple short-interest updates posted March 11–12.)
• Negative Sentiment: Q4 EPS missed consensus: CAPR reported a loss of ($0.62) vs. analysts’ ($0.51) estimate. An EPS miss amid a biotech story often triggers immediate selling as investors re-price near-term execution and funding risk. MarketBeat Earnings Coverage

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.